13F Holdings
中文EN

INO INOVIO PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1055726 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-70.0%
TTM net income YoY20.8%
TTM EPS YoY54.2%
Revenue 3-yr CAGR-81.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-132,871.3%
Net margin-130,000.0%
FCF margin-136,074.5%
EBITDA margin-130,701.4%

Returns

ROE-183.5%
ROA-90.6%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets67.6%
Debt / equity0.00x
Current ratio1.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.04x
Accruals ratio3.9%
Payout ratio—
Capex / revenue437.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$65,343$217,756$832,010$10.26M$1.77M
R&D expense$54.21M$75.62M$86.68M$187.65M$249.24M
SG&A expense$32.68M$37.00M$47.58M$90.19M$53.75M
Operating income-$86.82M-$112.40M-$143.94M-$267.57M-$301.22M
Interest expense$0$177,833$1.22M$1.25M$1.94M
Pretax income-$84.95M-$107.25M-$135.12M-$277.65M-$303.22M
Income tax$0$0$0$0$0
Net income-$84.95M-$107.25M-$135.12M-$279.82M-$303.66M
EBITDA-$85.40M-$110.65M-$141.32M-$263.92M-$298.18M
EPS (basic)-1.81-3.95-6.09-14.07-17.45
EPS (diluted)-1.81-3.95-6.09-14.07-17.45
Weighted avg. shares (diluted)46.89M27.16M22.17M19.89M17.40M
Balance sheet
Cash & equivalents$44.27M$65.81M$14.31M$46.33M$71.14M
Short-term investments$14.24M$28.30M$130.98M$206.67M$330.17M
Receivables$450$1.20M$2.41M$1.70M$5.47M
Current assets$61.12M$97.83M$153.11M$315.24M$448.44M
PP&E, net$2.53M$3.66M$4.96M$7.73M$17.45M
Goodwill——$0$10.51M$10.51M
Intangibles——$0$2.13M$2.63M
Total assets$74.31M$113.20M$170.95M$348.53M$495.94M
Current liabilities$43.67M$35.33M$42.57M$96.87M$65.74M
Total liabilities$50.21M$44.69M$53.60M$126.17M$96.27M
Shareholders' equity$24.10M$68.50M$117.35M$222.36M$399.67M
Shares outstanding69.00M36.10M22.79M21.09M217.38M
Cash flow statement
Operating cash flow-$88.63M-$104.08M-$124.37M-$216.22M-$215.71M
Capital expenditure$285,698$487,832$320,898$969,153$1.23M
Free cash flow-$88.92M-$104.56M-$124.69M-$217.18M-$216.94M
Investing cash flow$14.04M$104.07M$87.36M$109.59M-$175.34M
Financing cash flow$53.05M$51.48M$5.00M$81.84M$211.50M
Depreciation & amortization$1.42M$1.75M$2.62M$3.66M$3.04M
Stock-based compensation$3.76M$6.60M$11.07M$22.56M$26.34M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.